Platelet inhibition with tirofiban early during percutaneous coronary intervention: Dosing revisited

This publication has 16 references indexed in Scilit:

• Use of ICHOR-platelet works to assess platelet function in patients treated with GP IIb/IIIa inhibitors
  Catheterization and Cardiovascular Interventions, 2001
• Point-of-Care Measured Platelet Inhibition Correlates With a Reduced Risk of an Adverse Cardiac Event After Percutaneous Coronary Intervention
  Circulation, 2001
• Antiplatelet effects of abciximab, tirofiban and eptifibatide in patients undergoing coronary stenting
  Journal of the American College of Cardiology, 2001
• A comparative study of light transmission aggregometry and automated bedside platelet function assays in patients undergoing percutaneous coronary intervention and receiving abciximab, eptifibatide, or tirofiban
  Catheterization and Cardiovascular Interventions, 2001
• Rapid Platelet-Function Assay
  Circulation, 1999
• Randomised placebo-controlled and balloon-angioplasty-controlled trial to assess safety of coronary stenting with use of platelet glycoprotein-IIb/IIIa blockade
  The Lancet, 1998
• Effects of Platelet Glycoprotein IIb/IIIa Blockade With Tirofiban on Adverse Cardiac Events in Patients With Unstable Angina or Acute Myocardial Infarction Undergoing Coronary Angioplasty
  Circulation, 1997
• Platelet Glycoprotein IIb/IIIa Receptor Blockade and Low-Dose Heparin during Percutaneous Coronary Revascularization
  New England Journal of Medicine, 1997
• Randomised placebo-controlled trial of effect of eptifibatide on complications of percutaneous coronary intervention: IMPACT-II
  The Lancet, 1997
• Use of a Monoclonal Antibody Directed against the Platelet Glycoprotein IIb/IIIa Receptor in High-Risk Coronary Angioplasty
  New England Journal of Medicine, 1994